[go: up one dir, main page]

NO20081526L - Farmasoytisk preparat med fremragende fotostabilitet - Google Patents

Farmasoytisk preparat med fremragende fotostabilitet

Info

Publication number
NO20081526L
NO20081526L NO20081526A NO20081526A NO20081526L NO 20081526 L NO20081526 L NO 20081526L NO 20081526 A NO20081526 A NO 20081526A NO 20081526 A NO20081526 A NO 20081526A NO 20081526 L NO20081526 L NO 20081526L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
pitavastatin
excellent photo
photo stability
stability
Prior art date
Application number
NO20081526A
Other languages
English (en)
Norwegian (no)
Inventor
Masato Kozaki
Yoshio Tanizawa
Hiroyuki Kawashima
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NO20081526L publication Critical patent/NO20081526L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/501Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20081526A 2005-10-31 2008-03-28 Farmasoytisk preparat med fremragende fotostabilitet NO20081526L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005316758 2005-10-31
PCT/JP2006/321632 WO2007052592A1 (ja) 2005-10-31 2006-10-30 光安定性に優れた医薬製剤

Publications (1)

Publication Number Publication Date
NO20081526L true NO20081526L (no) 2008-07-29

Family

ID=38005744

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081526A NO20081526L (no) 2005-10-31 2008-03-28 Farmasoytisk preparat med fremragende fotostabilitet

Country Status (23)

Country Link
US (1) US20090041843A1 (ru)
EP (1) EP1944029B1 (ru)
JP (3) JP5166876B2 (ru)
KR (1) KR101409087B1 (ru)
CN (1) CN101300010B (ru)
AT (1) ATE537827T1 (ru)
AU (1) AU2006309826B2 (ru)
CA (1) CA2626309A1 (ru)
CY (1) CY1112477T1 (ru)
DK (1) DK1944029T3 (ru)
EA (1) EA016713B1 (ru)
ES (1) ES2375643T3 (ru)
IL (1) IL190346A (ru)
NO (1) NO20081526L (ru)
NZ (1) NZ566872A (ru)
PL (1) PL1944029T3 (ru)
PT (1) PT1944029E (ru)
SG (1) SG196789A1 (ru)
SI (1) SI1944029T1 (ru)
TW (1) TWI422375B (ru)
UA (1) UA92920C2 (ru)
WO (1) WO2007052592A1 (ru)
ZA (1) ZA200803655B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
KR20110117133A (ko) * 2009-01-29 2011-10-26 다이닛본 스미토모 세이야꾸 가부시끼가이샤 내핵을 갖는 구강 내 붕괴 정
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
JP2012041290A (ja) * 2010-08-18 2012-03-01 Sawai Pharmaceutical Co Ltd ラフチジン含有固形製剤
JP5809467B2 (ja) * 2011-07-12 2015-11-11 エルメッド エーザイ株式会社 ピタバスタチン含有組成物及びその製造方法
JP5844573B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する錠剤
JP5844574B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する安定化された薬物組成物
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀(pitavastatin)穩定配方的醫藥組合物
EP3269362A1 (en) 2012-08-08 2018-01-17 KOWA Co., Ltd. Pharmaceutical composition comprising pitavastatine
LT3003284T (lt) 2013-06-06 2020-04-27 Fibrogen, Inc. Hif hidroksilazės inhibitoriaus farmacinės kompozicijos
JP6150703B2 (ja) * 2013-10-08 2017-06-21 ダイト株式会社 ピタバスタチンカルシウム塩の分解抑制方法
JP6243265B2 (ja) * 2014-03-20 2017-12-06 日医工株式会社 ロスバスタチン含有医薬製剤
JP6433400B2 (ja) * 2014-09-30 2018-12-05 株式会社三和化学研究所 HMG−CoAレダクターゼ阻害薬を含有する医薬製剤
CN104367560A (zh) * 2014-10-23 2015-02-25 万全万特制药江苏有限公司 一种新型匹伐他汀钙口腔崩解片组合物及其制备方法
EP3272345B1 (en) 2015-03-19 2019-10-16 Daiichi Sankyo Company, Limited Solid preparation containing antioxidant agent
CA2980097C (en) * 2015-03-19 2019-10-29 Daiichi Sankyo Company, Limited Solid preparation containing colorant
JP6072884B2 (ja) * 2015-11-19 2017-02-01 共和薬品工業株式会社 ピタバスタチンを含有する製剤
EP3574906B1 (en) 2017-01-30 2024-07-03 Shionogi & Co., Ltd. Solid preparation comprising quinazoline derivative
TWI795462B (zh) 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
JP7166754B2 (ja) 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
CN108543075A (zh) * 2018-04-29 2018-09-18 广东伊茗药业有限公司 一种光稳定性优异的医药制剂
KR102849723B1 (ko) 2018-07-30 2025-08-22 다이이찌 산쿄 가부시키가이샤 안정화제를 함유하는 의약품의 고형 제제
EA202191371A1 (ru) * 2018-12-14 2021-12-27 Фуджифилм Корпорэйшн Фармацевтическая композиция и способ ее получения
CN112402388A (zh) * 2019-08-05 2021-02-26 江苏亚虹医药科技股份有限公司 一种用于治疗膀胱癌的口服固体制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU432703A3 (ru) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
JPS5522645A (en) 1978-08-07 1980-02-18 Fujisawa Pharmaceut Co Ltd Soft capsule for encapsulation of light-unstable compound
JPS6059205B2 (ja) * 1981-12-24 1985-12-24 帝三製薬株式会社 光不安定性薬物を包容するための軟カプセルの製造方法
JPS61275214A (ja) * 1985-05-28 1986-12-05 Sawai Seiyaku Kk 経口用メナテトレノン軟カプセル
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
DE4446470A1 (de) * 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
US6465477B1 (en) * 1997-08-18 2002-10-15 Kowa Company, Ltd. Stable pharmaceutical composition
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
JP2000191516A (ja) * 1998-10-23 2000-07-11 Taisho Pharmaceut Co Ltd 経口固形組成物
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2003104887A (ja) * 2001-09-28 2003-04-09 Maruko Seiyaku Kk 光に安定なアラニジピン含有組成物
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
US8158148B2 (en) * 2004-05-21 2012-04-17 Accu-Break Technologies, Inc. Pharmaceutical tablets comprising two or more unitary segments
CN101217944A (zh) * 2005-04-08 2008-07-09 艾博特公司 包含非诺贝酸和/或其盐的口服药物制剂

Also Published As

Publication number Publication date
SI1944029T1 (sl) 2012-03-30
PT1944029E (pt) 2012-02-09
SG196789A1 (en) 2014-02-13
CY1112477T1 (el) 2015-12-09
EP1944029B1 (en) 2011-12-21
DK1944029T3 (da) 2012-01-23
JP2012246325A (ja) 2012-12-13
NZ566872A (en) 2010-12-24
CA2626309A1 (en) 2007-05-10
EA016713B1 (ru) 2012-07-30
AU2006309826A1 (en) 2007-05-10
WO2007052592A1 (ja) 2007-05-10
ATE537827T1 (de) 2012-01-15
EP1944029A1 (en) 2008-07-16
CN101300010A (zh) 2008-11-05
TWI422375B (zh) 2014-01-11
HK1124772A1 (en) 2009-07-24
EP1944029A4 (en) 2011-01-12
ES2375643T3 (es) 2012-03-02
ZA200803655B (en) 2009-10-28
US20090041843A1 (en) 2009-02-12
JP2013014610A (ja) 2013-01-24
TW200800191A (en) 2008-01-01
CN101300010B (zh) 2012-06-06
KR20080058449A (ko) 2008-06-25
JP5166876B2 (ja) 2013-03-21
JPWO2007052592A1 (ja) 2009-04-30
JP5677391B2 (ja) 2015-02-25
IL190346A0 (en) 2009-09-22
IL190346A (en) 2013-06-27
EA200800993A1 (ru) 2008-08-29
PL1944029T3 (pl) 2012-05-31
KR101409087B1 (ko) 2014-06-17
AU2006309826B2 (en) 2012-01-19
UA92920C2 (ru) 2010-12-27

Similar Documents

Publication Publication Date Title
NO20081526L (no) Farmasoytisk preparat med fremragende fotostabilitet
DK1487444T3 (da) Anvendelse af pyridylamider som angiogeneseinhibitorer
NO20090370L (no) Kombinasjon av HMG-Coa-reduktaseinhibitor rosuvastatin med en fosfodiesterase 4-inhibitor, som roflumilast, roflumilast-N-oxid for behandling av inflammatoriske lungesykdommer.
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
AU2003245313A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
EP2300453A4 (en) 3.4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENININHIBITORS
EP2274295A4 (en) 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
BRPI0412636A (pt) imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
BR0200536A (pt) Compostos de sulfonilpiridazinana úteis como inibidores de aldose reductase
FR2896158B1 (fr) Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
DE60231568D1 (de) Verwendung von Pyrrolederivaten gegen Angstzustände
DE602004029362D1 (de) Vermeidung von vorhofflimmern (af) mit der verwendung von statin
EA200501499A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ п-ДИАМИНОБЕНЗОЛА
NO20080722L (no) Anvendelse av 4-(3,4-dijklorfenyl)-1,2,3,4-tetrahydronaftalen-1-ylamin for behandling av kreft
TH93113B (th) ผลิตภัณฑ์ทางเภสัชกรรมที่มีความเสถียรต่อแสงดีเยี่ยม
EA200700322A1 (ru) Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов
WO2006027344A3 (en) 3-oxa-10-aza-phenanthrenes as pde4 or pde3/4 inhibitors
WO2007006922A3 (fr) Nouveaux derives 1h-indole-pyridinecarboxamides et 1h-indole-piperidinecarboxamide et leur utilisation comme inducteurs de tyrosine hydroxylase
DK1601361T3 (da) Pyridylsulfonamidopyrimidiner til behandling af iabetisk nefropati
WO2006106427A8 (en) 7-fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application